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Purpose of the study
Clinical, immunological and virologic parameters were
assessed in HIV-infected antiretroviral (ARV) naïve
patients who started therapy with either Truvada ® (TVD)
or Combivir® (CBV) in combination with efavirenz (EFV)
or a protease inhibitor (PI).
Methods
107 HIV-infected, ARV-naïve patients were prospectively
enrolled and treated with TVD (300 mg TDF + 200 mg
FTC QD) or CBV (300 mg AZT + 150 mg 3TC BID) in
combination with EFV (600 mg QD) or a PI (LPV/r, ATV/
r, fAPV/r and SQV/r). Twenty-seven patients received
TVD-EFV, 33 received TVD-PI, 24 received CBV-EFV, and
23 received CBV-PI. Fifty-one of these patients have, so
far, reached 12 months of therapy. Clinical, immunologi-
cal and virologic parameters at baseline and after 12
months of therapy are presented.
Summary of results
Median CD4+ cell counts and HIV-RNA plasma viremia
were comparable in the four groups at baseline. EFV-asso-
ciated skin rash was observed in three of the TVD- and in
one of the CBV-treated patients. Eight patients in the TVD
groups (three TVD-EFV and five TVD-PI) and 12 patients
in the CBV groups (seven CBV-EFV and five CBV-PI)
dropped out of the study; in only two cases (one TVD:
acute pancreatitis; one CBV: leucopenia) was the drop-out
was due to SAE.
At month 12, HIV-RNA plasma viremia was < 50 cps/ml
in all patients; median CD4 cell counts were higher,
although not significantly, in EFV-treated patients: TDV-
EFV = 462/mcl (IQR: 323–663.5); TDV-PI = 339/mcl
(IQR: 298–365); CBV-EFV = 450/mcl (IQR: 388.75–
525.75); CBV+PI = 390/mcl (IQR: 308–523). Median
CD4 counts were significantly different, compared to
baseline values, in TDV-EFV (p = 0.01); TDV-PI (p = 0.03);
and CBV-EFV (p = 0.02) groups.
Interestingly, whereas CD8+/CD38+/CDRO+ T lym-
phocytes were significantly diminished (median delta
T12-baseline) after 12 months of therapy in all groups of
patients, a significant reduction of CD8+/CD25+ and of
CD8+/DRII+ T lymphocytes (p = 0.01 and 0.02, respec-
tively) was observed at month 12 only in the TVD-EFV
group.
Conclusion
Although the four therapeutic regimens considered do not
differ significantly in the ability to suppress HIV viremia,
the TVD-EFV combination is associated with a significant
down-modulation of immune activation. In the light of
the increasing importance of immune activation in the
pathogenesis of HIV infection, the ability of this combina-
tion to reduce this parameter seems potentially impor-
tant.
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